{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:29:10Z","timestamp":1761895750031},"reference-count":53,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1053\/j.seminoncol.2013.07.008","type":"journal-article","created":{"date-parts":[[2013,10,14]],"date-time":"2013-10-14T22:45:13Z","timestamp":1381790713000},"page":"602-609","source":"Crossref","is-referenced-by-count":7,"title":["New Developments in Post-transplant Maintenance Treatment of Multiple Myeloma"],"prefix":"10.1053","volume":"40","author":[{"given":"Hong","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2013.07.008_bib1","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3109\/10428194.2012.717277","article-title":"Evolving therapeutic paradigms for multiple myeloma: back to the future","volume":"54","author":"Cherry","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V31.1.1.1","article-title":"Melphalan therapy for plasma cell myeloma","volume":"31","author":"Alexanian","year":"1968","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib3","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib4","first-page":"147","volume":"135","year":"1975","journal-title":"Remission maintenance therapy for multiple myeloma. Arch Intern Med"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib5","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/bjc.1988.17","article-title":"A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients","volume":"57","author":"Belch","year":"1988","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib6","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.2.5970.557","article-title":"Letter: Maintenance therapy in myeloma: risk versus benefit","volume":"2","author":"Sieber","year":"1975","journal-title":"Br Med J"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib7","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1056\/NEJM197910043011402","article-title":"The chemotherapy on plasma-cell myeloma and the incidence of acute leukemia","volume":"301","author":"Bergsagel","year":"1979","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib8","first-page":"697","article-title":"Interferon therapy in myelomatosis","volume":"2","author":"Mellstedt","year":"1979","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib9","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1046\/j.1365-2141.2001.02857.x","article-title":"Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients","volume":"113","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib10","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1023\/A:1026548226770","article-title":"Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients","volume":"11","author":"Fritz","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib11","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1093\/annonc\/mdi125","article-title":"Interferon-alpha as maintenance therapy in patients with multiple myeloma","volume":"16","author":"Schaar","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib12","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood.V62.3.572.572","article-title":"Prednisone pulse therapy for refractory myeloma","volume":"62","author":"Alexanian","year":"1983","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib13","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/sj.bmt.1704633","article-title":"Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma","volume":"34","author":"Kumar","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib14","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJM198405243102104","article-title":"Effective treatment of advanced multiple myeloma refractory to alkylating agents","volume":"310","author":"Barlogie","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib15","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1200\/JCO.2007.12.3323","article-title":"Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics","volume":"25","author":"Rosinol","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib16","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1200\/JCO.1998.16.3.890","article-title":"Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study","volume":"16","author":"Salmon","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib17","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1182\/blood.V99.9.3163","article-title":"Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients","volume":"99","author":"Berenson","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib18","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/1096-8652(200011)65:3<204::AID-AJH5>3.0.CO;2-H","article-title":"Randomized trial of alpha-interferon or dexamethasone as maintenance treatment for multiple myeloma","volume":"65","author":"Alexanian","year":"2000","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib19","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1365-2141.2006.06405.x","article-title":"A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7","volume":"136","author":"Shustik","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib20","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(62)91248-5","article-title":"Thalidomide and congenital abnormalities","volume":"1","author":"Speirs","year":"1962","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib21","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","article-title":"Thalidomide is an inhibitor of angiogenesis","volume":"91","author":"D'Amato","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib22","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib23","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib24","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","article-title":"Maintenance therapy with thalidomide improves survival in patients with multiple myeloma","volume":"108","author":"Attal","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib25","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJMoa053583","article-title":"Thalidomide and hematopoietic-cell transplantation for multiple myeloma","volume":"354","author":"Barlogie","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib26","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1200\/JCO.2008.18.8573","article-title":"Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure","volume":"27","author":"Spencer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib27","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood-2009-05-222539","article-title":"A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma","volume":"115","author":"Lokhorst","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib28","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1182\/blood-2012-09-451872","article-title":"A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial","volume":"121","author":"Stewart","year":"2013","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib29","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2011-06-357038","article-title":"The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis","volume":"119","author":"Morgan","year":"2012","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib30","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/ajh.23274","article-title":"Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma","volume":"87","author":"Maiolino","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib31","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2009.25.6081","article-title":"Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences","volume":"28","author":"Barlogie","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib32","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1182\/blood-2008-03-145235","article-title":"Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities","volume":"112","author":"Barlogie","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib33","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.leukres.2012.04.001","article-title":"Thalidomide maintenance therapy for patients with multiple myeloma: meta-analysis","volume":"36","author":"Kagoya","year":"2012","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib34","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4049\/jimmunol.163.1.380","article-title":"Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha","volume":"163","author":"Corral","year":"1999","journal-title":"J Immunol"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib35","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/JCO.2009.22.7561","article-title":"Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients","volume":"28","author":"Palumbo","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib36","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib37","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib38","first-page":"1142a","article-title":"Lenalidomide maintenance significantly reduces the risk of progression in newly diagnosed young multiple myeloma patients enrolled in RV-MM-PI-209 trial","author":"Cavallo F","year":"2012","journal-title":"Haematologica"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib39","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib40","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib41","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib42","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1586\/17474086.1.1.17","article-title":"Role of bortezomib for the treatment of previously untreated multiple myeloma","volume":"1","author":"Mateos","year":"2008","journal-title":"Exp Rev Hematol"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib43","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.1200\/JCO.2010.28.3945","article-title":"Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p)","volume":"28","author":"Avet-Loiseau","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib44","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib45","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2141.2007.06639.x","article-title":"Incorporating bortezomib into upfront treatment for multiple myeloma: early results of Total Therapy 3","volume":"138","author":"Barlogie","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib46","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/ GMMG-HD4 trial","volume":"30","author":"Sonneveld","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib47","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial","volume":"28","author":"Palumbo","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib48","first-page":"200","article-title":"Overall Survival Benefit for Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance with Bortezomib-Thalidomide (VMPT-VT) Versus Bortezomib-Melphalan-Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients","volume":"120","author":"Palumbo","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib49","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1182\/blood-2012-05-427815","article-title":"Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial","volume":"120","author":"Mateos","year":"2012","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib50","first-page":"334","article-title":"Maintenance Therapy After Stem-Cell Transplantation for Multiple Myeloma with Bortezomib\/Thalidomide Vs. Thalidomide Vs. alfa2b-Interferon: Final Results of a Phase III Pethema\/GEM Randomized Trial","volume":"120","author":"Rosinnol","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib51","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib52","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S1470-2045(11)70157-7","article-title":"Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial","volume":"12","author":"Morgan","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2013.07.008_bib53","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1182\/blood-2011-11-374249","article-title":"IMWG consensus on maintenance therapy in multiple myeloma","volume":"119","author":"Ludwig","year":"2012","journal-title":"Blood"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775413001322?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775413001322?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T09:46:59Z","timestamp":1688550419000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775413001322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0093775413001322"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2013.07.008","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]}}}